Drug Trial Radar · NCT00359567
Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy
Last checked: Nov 20, 2026Latest source record: Jul 7, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,140
Planned (sponsor's estimate)
Start
Jul 2006
Primary completion
May 2007
Study completion Aug 2007
Sponsor
- Lead sponsor
- Taiho Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 2, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare palonosetron with granisetron hydrochloride as a control in the efficacy of intravenous single dose in preventing acute and delayed gastro-intestinal disorders, such as nausea and vomiting induced by highly emetogenic chemotherapy.
Conditions
- Chemotherapy-Induced Nausea and Vomiting
Interventions
palonosetronDrug
intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
granisetron hydrochlorideDrug
intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete response (CR: no emetic episodes and no rescue medication) rate in acute and delayed nausea and vomiting
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Cancer Center
5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.